about
Developing an HIV vaccine: the role of efficacy studies in nonhuman primatesCharacterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition.Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptidesCroup is associated with the novel coronavirus NL63Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaquesAntiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cellsEffect of lovastatin on coxsackievirus B3 infection in human endothelial cellsImmunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaquesApplication of the PAMONO-Sensor for Quantification of Microvesicles and Determination of Nano-Particle Size DistributionRev proteins of human and simian immunodeficiency virus enhance RNA encapsidation.Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunityHIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.Nuclear RNA export and packaging functions of HIV-1 Rev revisitedCCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particlesDivergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particlesSelection of a T7 promoter mutant with enhanced in vitro activity by a novel multi-copy bead display approach for in vitro evolutionThe HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNAReplication properties of human adenovirus in vivo and in cultures of primary cells from different animal speciesProtective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.Detection and quantification of human bocavirus in river water.Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypesCodelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with gagTargeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus.Efficacy of AIDS vaccine strategies in nonhuman primates.T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virusRisk of immunodeficiency virus infection may increase with vaccine-induced immune response.The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.A novel cardiotropic murine adenovirus representing a distinct species of mastadenoviruses.Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.Unintended spread of a biosafety level 2 recombinant retrovirus.GagPol-specific CD4⁺ T-cells increase the antibody response to Env by intrastructural help.Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.The human immunodeficiency virus type 1 Rev protein: ménage à trois during the early phase of the lentiviral replication cycle.Methods to detect infectious human enteric viruses in environmental water samples.
P50
Q24792383-21FC3791-1911-401E-B5F0-7316C6C4FB9FQ24797850-72B23B3F-AF43-4434-B572-2DE37FA70578Q24803217-164744C3-B36F-4BC7-9106-CE59CFE06A74Q24814848-A78685D3-5201-4F03-9D4F-4CC4B59C6900Q27317212-F6F4A856-2A3A-406F-B5E5-7777FE087067Q28279712-57214E1D-80B4-466F-8321-21ABA3D9E01BQ28303547-47CB47A2-6039-4335-8AB7-0AD4217B8D5AQ28728563-51F84B19-BBD8-43A7-8EC0-3D35365FE6BAQ30361056-FE52D8FC-D935-4594-9555-29C69DAC53E7Q33282047-C0BF465D-336F-4004-AAAC-29381D95DF10Q33327757-8BEA82E1-B3A7-4228-AD60-8F37C5E9AA99Q33366554-DC21D1C7-B47F-4336-B99B-AD38E4D7B9C0Q33489847-20E68339-BF24-4491-9B0B-DFF37CB72C0CQ33614622-AD84163A-E1BF-4FCA-93FC-324D1E3EC4CAQ33732729-9CDB9345-C2C4-4FC4-96F4-35252E3A9A0CQ33990559-4CA5C2FE-6375-4EE4-BF26-001A089C04A0Q34069656-BB0123CC-2401-4D80-848C-060322B6EB27Q34102311-9D251A40-EB42-4B30-BA2B-DB7FF37C2269Q34449126-2958F520-14A1-4B08-B23B-96F98B4DFDD2Q34469824-BB5F9090-974B-4BAB-9C2F-44143D2D7949Q34545667-6CAB3763-3DAA-4ADC-9464-CA4D9B22A696Q34964980-010545E6-F98A-4716-9AFA-6FC3AA89796FQ34995827-2DD52794-DDE3-4CE9-849F-CC37D5F8C9BEQ35353052-B12F492F-70BA-4F61-8617-148E4F94F733Q35689651-DB97AE25-0BD0-4CDA-AB3C-4FF6B3D636C2Q35826247-E640BD4B-BED5-47F5-9098-4593BC0F095FQ35998559-8B6BFDB9-7BBB-49E9-9182-4B3D08BA5C96Q36103593-A91BE519-DEC3-47E4-80C6-D6D2A4EBEBEFQ36127805-390D1368-3A30-4524-9860-6AC032842E8CQ36276637-0A0C29A8-C7DF-4E17-AC78-1099EA991042Q36489528-C88F471D-6B20-4A04-BD63-F045588FCCB6Q36853450-5DF0ECBA-A1FD-4F41-8FF7-FE578DF60F25Q37191886-B889DCB2-16EE-49EC-A4A9-70DC12D79C19Q37268317-2FBC48A0-9BC0-4B64-A677-7270096C2D67Q37384058-18EF64C9-FE8F-4269-8B90-8DCFD3EB9C87Q37418439-5AB58131-886A-4FD8-AC4B-097FF4100D4AQ37452172-19627A15-9C61-4192-B2BA-79AD371759D4Q37713895-B4C53275-8404-4BC5-B88B-03ECABCFC5DCQ37764251-14CCB04A-CAB5-4F07-94D9-B63206C8F69CQ37932830-8388C46D-5FCE-46FD-B5B3-82D8DC467DEC
P50
description
Virologe
@de
virologist
@en
name
Klaus Überla
@de
Klaus Überla
@en
type
label
Klaus Überla
@de
Klaus Überla
@en
altLabel
Klaus Thomas Überla
@en
Klaus Uberla
@en
prefLabel
Klaus Überla
@de
Klaus Überla
@en